Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

Journal of Hepatology

Volumn 63, Issue 4, 2015, Pages 952-961

  Munoz Garrido, Patricia ^a,b   Marin, José J G ^b,c   Perugorria, María J ^a,b,d   Urribarri, Aura D ^e   Erice, Oihane ^a   Sáez, Elena ^e   Úriz, Miriam ^e   Sarvide, Sarai ^e   Portu, Ainhoa ^b,e   Concepcion, Axel R ^e   Romero, Marta R ^b,c   Monte, María J ^b,c   Santos Laso, Álvaro ^a   Hijona, Elizabeth ^a,b   Jimenez Agüero, Raúl ^a   Marzioni, Marco ^f   Beuers, Ulrich ^g   Masyuk, Tatyana V ^h   Larusso, Nicholas F ^h   Prieto, Jesús ^b,e   Bujanda, Luis ^a,b   Drenth, Joost P H ⁱ   Banales, Jesús M ^a,b,d,e,j   more..

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b National Institute for the Study of Liver and Gastrointestinal Diseases   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

^e UNIVERSITY OF NAVARRA   (Spain)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h MAYO CLINIC   (United States)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HOSPITAL DONOSTIA   (Spain)

more..

Author keywords

Cholangiocyte; Cystogenesis; Intracellular calcium; Polycystic liver diseases (PLDs); Therapy; Ursodeoxycholic acid (UDCA)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CXCL1 CHEMOKINE; GLYCODEOXYCHOLIC ACID; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA1; UREA; URSODEOXYCHOLIC ACID; CALCIUM; CHOLAGOGUE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; LIVER; LIVER CYST; LIVER FIBROSIS; LIVER POLYCYSTIC DISEASE; LOCOMOTION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SERUM; TANDEM MASS SPECTROMETRY; UREA BLOOD LEVEL; ANIMAL; BILE DUCT; CELL CULTURE; CYSTS; DISEASE MODEL; DRUG EFFECTS; LIVER DISEASES; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; BILE DUCTS; CALCIUM; CELL PROLIFERATION; CELLS, CULTURED; CHOLAGOGUES AND CHOLERETICS; CYSTS; DISEASE MODELS, ANIMAL; LIVER; LIVER DISEASES; RATS; TANDEM MASS SPECTROMETRY; URSODEOXYCHOLIC ACID;

EID: 84941933532     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.05.023     Document Type: Article

References (30)

1. T.J. Gevers, and J.P. Drenth Diagnosis and management of polycystic liver disease Nat Rev Gastroenterol Hepatol 10 2013 101 108
2. M.J. Perugorria, T.V. Masyuk, J.J. Marin, M. Marzioni, L. Bujanda, N.F. LaRusso, and et al. Polycystic liver diseases: advanced insights into the molecular mechanisms Nat Rev Gastroenterol Hepatol 11 2014 750 761
3. A. Caroli, L. Antiga, M. Cafaro, G. Fasolini, A. Remuzzi, G. Remuzzi, and et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide Clin J Am Soc Nephrol 5 2010 783 789
4. M.C. Hogan, T.V. Masyuk, L. Page, D.R. Holmes 3rd, X. Li, E.J. Bergstralh, and et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years Nephrol Dial Transplant 27 2012 3532 3539
5. M.C. Hogan, T.V. Masyuk, L.J. Page, V.J. Kubly, E.J. Bergstralh, X. Li, and et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 2010 1052 1061
6. T.V. Masyuk, A.I. Masyuk, V.E. Torres, P.C. Harris, and N.F. Larusso Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate Gastroenterology 132 2007 1104 1116
7. M. Chrispijn, F. Nevens, T.J. Gevers, R. Vanslembrouck, M.G. van Oijen, W. Coudyzer, and et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide Aliment Pharmacol Ther 35 2012 266 274
8. F. Temmerman, T. Gevers, T.A. Ho, R. Vanslembrouck, W. Coudyzer, J. van Pelt, and et al. Safety and efficacy of different lanreotide doses in the treatment of polycystic liver disease: pooled analysis of individual patient data Aliment Pharmacol Ther 38 2013 397 406
9. L. van Keimpema, F. Nevens, R. Vanslembrouck, M.G. van Oijen, A.L. Hoffmann, H.M. Dekker, and et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial Gastroenterology 137 2009 1661 1668
10. T.V. Masyuk, B.N. Radtke, A.J. Stroope, J.M. Banales, S.A. Gradilone, B. Huang, and et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases Hepatology 58 2013 409 421
11. J.M. Banales, T.V. Masyuk, S.A. Gradilone, A.I. Masyuk, J.F. Medina, and N.F. LaRusso The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD) Hepatology 49 2009 160 174
12. U. Beuers Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis Nat Clin Pract Gastroenterol Hepatol 3 2006 318 328
13. R. Poupon Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action Clin Res Hepatol Gastroenterol 36 2012 S3 S12
14. G. Alpini, L. Baiocchi, S. Glaser, Y. Ueno, M. Marzioni, H. Francis, and et al. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha Hepatology 35 5 2002 1041 1052
15. 2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts Am J Pathol 168 2006 398 409
16. S.B. Mason, Y. Liang, R.M. Sinders, C.A. Miller, T. Eggleston-Gulyas, R. Crisler-Roberts, and et al. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD Anat Rec (Hoboken) 293 2010 1279 1288
17. T.V. Masyuk, B.Q. Huang, A.I. Masyuk, E.L. Ritman, V.E. Torres, X. Wang, and et al. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease Am J Pathol 165 2004 1719 1730
18. A.D. Urribarri, P. Munoz-Garrido, M.J. Perugorria, O. Erice, M. Merino-Azpitarte, A. Arbelaiz, and et al. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases Gut 63 2014 1658 1667
19. M.J. Monte, M.C. Martinez-Diez, M.Y. El-Mir, M.E. Mendoza, P. Bravo, O. Bachs, and et al. Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration J Hepatol 36 2002 534 542
20. N.S. Nytofte, M.A. Serrano, M.J. Monte, E. Gonzalez-Sanchez, Z. Tumer, K. Ladefoged, and et al. A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis J Med Genet 48 2011 219 225
21. C. Song, X.Y. Zhang, and M. Manku Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment J Neurosci 29 2009 14 22
22. M.A. Muff, T.V. Masyuk, A.J. Stroope, B.Q. Huang, P.L. Splinter, S.O. Lee, and et al. Development and characterization of a cholangiocyte cell line from the PCK rat, an animal model of Autosomal Recessive Polycystic Kidney Disease Lab Invest 86 9 2006 940 950
23. J.M. Banales, T.V. Masyuk, P.S. Bogert, B.Q. Huang, S.A. Gradilone, S.O. Lee, and et al. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease Am J Pathol 173 2008 1637 1646
24. T.V. Masyuk, S.O. Lee, B.N. Radtke, A.J. Stroope, B. Huang, J.M. Banales, and et al. Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression Am J Pathol 184 2014 110 121
25. S.O. Lee, T. Masyuk, P. Splinter, J.M. Banales, A. Masyuk, A. Stroope, and et al. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease J Clin Invest 118 2008 3714 3724
26. C. Spirli, L. Locatelli, R. Fiorotto, C.M. Morell, L. Fabris, T. Pozzan, and et al. Altered store operated calcium entry increases cyclic 3′,5′-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes Hepatology 55 2012 856 868
27. G. De Marco, D. Sordino, E. Bruzzese, S. Di Caro, D. Mambretti, A. Tramontano, and et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure Aliment Pharmacol Ther 24 2006 387 394
28. D. Rost, G. Rudolph, P. Kloeters-Plachky, and A. Stiehl Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis Hepatology 40 2004 693 698
29. P. Angulo, E.R. Dickson, T.M. Therneau, R.A. Jorgensen, C. Smith, C.K. DeSotel, and et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial J Hepatol 30 1999 830 835
30. M.A. Kotb Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode Int J Mol Sci 13 2012 8882 8914